-
5/21/2024
AstraZeneca revealed its bold ambition to deliver$80billion in Total Revenue by2030，up from$45.8billion in 2023。
-
5/21/2024
Cantargia Cantargia announced its interim report for the first quarter of 2024。
-
5/21/2024
IRLB Therapeutics AB，a company discovering and developing novel treatments for Parkinson's disease，announced that the company will present at ABGSC Investor Days in Stockholm on Thursday，May23。
-
5/21/2024
.Hansa Biopharma，“Hansa”，announced data featuring imlifidase will be presented at the American Transplant Congress，the joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation。
-
5/21/2024
Innate Pharma SA announced that in an abstract published on 14 May2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101，submitted by Sanofi，it was mentioned that the molecule received breakthrough designation。
-
5/21/2024
Genentech，a member of the Roche Group，announced that the FDA has granted Breakthrough Therapy Desition for inavolisib，an investigational oral therapy，in combination with palbociclib and fulvestrant，for the treatment of adult patients with PIK3CA-mutated，hormone receptor-positive，hurma manceptor，hurmaceth gative，locally advanced or metastatic breast cancer，following recurrence on or within12months of completing adjuvant endocrine treatment。
-
5/21/2024
Valneva SE，aspecialty vaccine company，announced the appointment of Dr.Hanneke Schuitemaker，Ph.D.as Chief Scientific Officer and Executive Committee member，effective June3224。
-
5/21/2024
Astellas Pharma Inc.announced that it signed a memorandum of understanding with YASKAWA Electric Corporation to begin discussions on the creation of an innovative cell therapy ecosystem through the integration of pharmaceutical and robotics technologies。
-
5/21/2024
Innovent Biologics，Inc.announced that the New Drug Application for IBI311，arecombinant anti-insulin-like growth factor 1 receptor antibody，has been accepted and granted priority review designation by the Center for Drug Evaluation of the China National Drug Administration for the treatment of Thyroid Eye Disease。
-
5/21/2024
Teva Pharmaceuticals，aU.S.affiliate of Teva Pharmaceutical Industries Ltd.and Alvotech，announced the availability of SIMLANDI injection in the U.S.，as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis，juvenile idiopathic arthritis，adult sopulthic ing spondylitis，Crohn’s disease，adult ulcerative colitis，adult playque psoriasis，adult hidradenitis suppurativa and adult uveitis。
-
To support its growing antibody-drug conjugate portfolio，AstraZeneca on Monday said it is investing$1.5 billion in a Singapore production site that will include all steps of the ADC manufacturing process。
-
While Eli Lilly and Novo Nordisk currently dominate the GLP-1receptor agonist space，there are more than50candidates in clinical development for obesity and type2diabetes，according to analytics firm GlobalData。
-
Seladelpar，which Gilead acquired when it bought CymaBay in February for$4.3 billion，showed positive results for reducing pruritus in primary biliary cholangities patients and reducing inflammation。
-
Neuroscience-focused Rapport Therapeutics and radiopharma developer Telix Pharma announced their respective plans Friday for initial public offerings on the Nasdaq for undisclosed dollar amounts。
-
The European Patent Office last week upheld one of Moderna’s key patents，handing the biotech an important victory in its protracted COVID-19vaccine battle with Pfizer and BioNTech。
-
Life science companies can protect intellectual property in multiple ways，including leveraging IP rights。
-
Pfizer’s Wyeth unit notched a legal victory over AstraZeneca on Friday as a federal jury found the British-Swedish company violated two key patents in developing and marketing its lung cancer drug Tagrisso。
-
5/20/2024
Perosphere Technologies today announced Michael A.Grosso，MD，FACS，joins its Advisory Board。
-
5/20/2024
Danimer Scientific，Inc.announced today that Stephen E.Croskrey has informed the Board of Directors that he will retire as Chief Executive Officer not later than the end of this calendar year。
-
5/20/2024
Atara Biotherapeutics Submits Tabelecleucel（Tab-cel）®）Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S.FDA。
